Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice.

Roth C, Cantaert T, Colas C, Prot M, Casadémont I, Levillayer L, Thalmensi J, Langlade-Demoyen P, Gerke C, Bahl K, Ciaramella G, Simon-Loriere E, Sakuntabhai A.

Front Immunol. 2019 Jun 21;10:1424. doi: 10.3389/fimmu.2019.01424. eCollection 2019.

2.

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.

Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, Himansu S, Diamond MS, Crowe JE Jr.

Sci Immunol. 2019 May 17;4(35). pii: eaaw6647. doi: 10.1126/sciimmunol.aaw6647.

PMID:
31101672
3.

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.

Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, Laska ME, Thompson J, Zaks T, Ciaramella G.

Vaccine. 2019 May 31;37(25):3326-3334. doi: 10.1016/j.vaccine.2019.04.074. Epub 2019 May 10.

4.

Corrigendum: Induction of Robust B Cell Responses After Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells.

Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, Bahl K, John S, Yuzhakov O, Hassett KJ, Brito LA, Salter H, Ciaramella G, Loré K.

Front Immunol. 2019 Apr 2;10:614. doi: 10.3389/fimmu.2019.00614. eCollection 2019.

5.

Uncovering critical properties of the human respiratory syncytial virus by combining in vitro assays and in silico analyses.

Beauchemin CAA, Kim YI, Yu Q, Ciaramella G, DeVincenzo JP.

PLoS One. 2019 Apr 15;14(4):e0214708. doi: 10.1371/journal.pone.0214708. eCollection 2019.

6.

Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines.

Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, Himansu S, Deterling J, Geilich BM, Ketova T, Mihai C, Lynn A, McFadyen I, Moore MJ, Senn JJ, Stanton MG, Almarsson Ö, Ciaramella G, Brito LA.

Mol Ther Nucleic Acids. 2019 Apr 15;15:1-11. doi: 10.1016/j.omtn.2019.01.013. Epub 2019 Feb 7.

7.

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, Ciaramella G.

Vaccine. 2018 Mar 14;36(12):1689-1699. doi: 10.1016/j.vaccine.2018.01.029. Epub 2018 Feb 15.

8.

Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease.

Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A.

J Infect Dis. 2018 Jan 17;217(3):451-455. doi: 10.1093/infdis/jix592.

9.

Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells.

Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, Bahl K, John S, Yuzhakov O, Hassett KJ, Brito LA, Salter H, Ciaramella G, Loré K.

Front Immunol. 2017 Nov 13;8:1539. doi: 10.3389/fimmu.2017.01539. eCollection 2017. Erratum in: Front Immunol. 2019 Apr 02;10:614.

10.

Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination.

Lin A, Liang F, Thompson EA, Vono M, Ols S, Lindgren G, Hassett K, Salter H, Ciaramella G, Loré K.

J Immunol. 2018 Jan 1;200(1):286-294. doi: 10.4049/jimmunol.1701005. Epub 2017 Nov 27.

11.

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.

Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, John S, Hassett K, Yuzhakov O, Bahl K, Brito LA, Salter H, Ciaramella G, Loré K.

Mol Ther. 2017 Dec 6;25(12):2635-2647. doi: 10.1016/j.ymthe.2017.08.006. Epub 2017 Aug 12.

12.

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.

Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, Himansu S, Caine EA, Nunes BTD, Medeiros DBA, Muruato AE, Foreman BM, Luo H, Wang T, Barrett AD, Weaver SC, Vasconcelos PFC, Rossi SL, Ciaramella G, Mysorekar IU, Pierson TC, Shi PY, Diamond MS.

Cell. 2017 Jul 13;170(2):273-283.e12. doi: 10.1016/j.cell.2017.06.040.

13.

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.

Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J, Ribeiro AM, Watson M, Zaks T, Ciaramella G.

Mol Ther. 2017 Jun 7;25(6):1316-1327. doi: 10.1016/j.ymthe.2017.03.035. Epub 2017 Apr 27.

14.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 23;169(1):176. doi: 10.1016/j.cell.2017.03.016. No abstract available.

15.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 9;168(6):1114-1125.e10. doi: 10.1016/j.cell.2017.02.017. Epub 2017 Feb 17. Erratum in: Cell. 2017 Mar 23;169(1):176.

16.

Total shoulder replacement using a bone ingrowth central peg polyethylene glenoid component: a prospective clinical and computed tomography study with short- to mid-term follow-up.

Merolla G, Ciaramella G, Fabbri E, Walch G, Paladini P, Porcellini G.

Int Orthop. 2016 Nov;40(11):2355-2363. Epub 2016 Aug 10.

PMID:
27506572
17.

Long-term clinical results and MRI changes after autologous chondrocyte implantation in the knee of young and active middle aged patients.

Rosa D, Balato G, Ciaramella G, Soscia E, Improta G, Triassi M.

J Orthop Traumatol. 2016 Mar;17(1):55-62. doi: 10.1007/s10195-015-0383-6. Epub 2015 Oct 24.

18.

Treatment of Proximal Scaphoid Non-union by Resection of the Proximal Pole and Palmaris Longus Interposition Arthroplasty.

Smeraglia F, Ciaramella G, Cerbasi S, Balato G, Mariconda M.

Handchir Mikrochir Plast Chir. 2015 Jun;47(3):171-4. doi: 10.1055/s-0035-1548847. Epub 2015 Jun 17.

PMID:
26084856
19.

Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.

Flores MV, Hickling TP, Sreckovic S, Fidock MD, Horscroft N, Katragadda M, Savic B, Rawal J, Delpuech-Adams OE, Robas N, Corey T, Nelms L, Lawton M, Marcek J, Stubbs M, Westby M, Ciaramella G.

Antivir Ther. 2012;17(5):869-81. doi: 10.3851/IMP2099. Epub 2012 Apr 13. Erratum in: Antivir Ther.2012;17(5):939.

PMID:
22505586
20.

Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.

Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, Weber M, Lazari O, Perez-Tosar L, Fancy SA, Lapthorn C, Green MX, Evans S, Selby M, Jones G, Jones L, Kearney S, Mechiche H, Gikunju D, Subramanian R, Uhlmann E, Jurk M, Vollmer J, Ciaramella G, Yeadon M.

Mol Ther. 2011 Dec;19(12):2163-8. doi: 10.1038/mt.2011.206. Epub 2011 Oct 4.

21.

Discovery of a highly potent series of TLR7 agonists.

Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5939-43. doi: 10.1016/j.bmcl.2011.07.076. Epub 2011 Aug 4.

PMID:
21885277
22.

Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.

Tran TD, Pryde DC, Jones P, Adam FM, Benson N, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Gardner I, Jones HM, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2389-93. doi: 10.1016/j.bmcl.2011.02.092. Epub 2011 Mar 16.

PMID:
21419626
23.

HIV capsid is a tractable target for small molecule therapeutic intervention.

Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L, Hunt R, Kjerrstrom A, Nieman JA, Patick AK, Perros M, Scott AD, Whitby K, Wu H, Butler SL.

PLoS Pathog. 2010 Dec 9;6(12):e1001220. doi: 10.1371/journal.ppat.1001220.

24.

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.

Flores MV, Strawbridge J, Ciaramella G, Corbau R.

Biochim Biophys Acta. 2009 Oct;1794(10):1441-8. doi: 10.1016/j.bbapap.2009.06.004. Epub 2009 Jun 6.

PMID:
19505593
25.

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M.

J Virol. 2007 Mar;81(5):2359-71. Epub 2006 Dec 20.

26.

Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry.

Bradley J, Gill J, Bertelli F, Letafat S, Corbau R, Hayter P, Harrison P, Tee A, Keighley W, Perros M, Ciaramella G, Sewing A, Williams C.

J Biomol Screen. 2004 Sep;9(6):516-24.

PMID:
15452338
27.

High-throughput screening for ion channel modulators.

Falconer M, Smith F, Surah-Narwal S, Congrave G, Liu Z, Hayter P, Ciaramella G, Keighley W, Haddock P, Waldron G, Sewing A.

J Biomol Screen. 2002 Oct;7(5):460-5.

PMID:
14599362
28.

Measuring intracellular calcium fluxes in high throughput mode.

Chambers C, Smith F, Williams C, Marcos S, Liu ZH, Hayter P, Ciaramella G, Keighley W, Gribbon P, Sewing A.

Comb Chem High Throughput Screen. 2003 Jun;6(4):355-62.

PMID:
12769679
29.

Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein.

Wardell AD, Errington W, Ciaramella G, Merson J, McGarvey MJ.

J Gen Virol. 1999 Mar;80 ( Pt 3):701-9.

PMID:
10092010
30.

Interaction of proteins with a cytochrome P450 2B2 gene promoter: identification of two DNA sequences that bind proteins that are enriched or activated in response to phenobarbital.

Shephard EA, Forrest LA, Shervington A, Fernandez LM, Ciaramella G, Phillips IR.

DNA Cell Biol. 1994 Aug;13(8):793-804.

PMID:
8068204
31.

Cell systems capable of sustaining phenobarbital induction by CYP2B genes.

Ciaramella G, Edwards M, Shephard EA, Phillips IR.

Biochem Soc Trans. 1994 May;22(2):120S. No abstract available.

PMID:
7958191
32.

[Remote results in the treatment of bimalleolar fractures].

Ciaramella G, Savarese A, Guerini R.

Chir Organi Mov. 1987 Apr-Jun;72(2):93-8. Italian. No abstract available.

PMID:
3677877
33.

[On acromioclavicular luxation].

Ciaramella G, Nannei A.

Minerva Ortop. 1970 Mar;21(3):253-8. Italian. No abstract available.

PMID:
5478446
34.

[Lipomas and liposarcomas].

Ciaramella G.

Arch Ortop. 1968;81(5):263-77. Italian. No abstract available.

PMID:
5740592
35.

[ON PSEUDARTHROSIS OF THE PATELLA].

CIARAMELLA G.

Minerva Ortop. 1965 Apr;16:174-7. Italian. No abstract available.

PMID:
14342901
36.

[TREATMENT OF DIAPHYSEAL FRACTURES OF THE HUMERUS BY MEANS OF INTRAMEDULLARY OSTEOSYNTHESIS].

CIARAMELLA G.

Minerva Ortop. 1965 Apr;16:171-3. Italian. No abstract available.

PMID:
14342900
37.

[Electrophoretic research on natural sera and sera after denaturation in patients with fractures of the skeletal apparatus].

Ciaramella G, Ottaviani C.

Boll Soc Ital Biol Sper. 1965 Mar 15;41(5):265-7. Italian. No abstract available.

PMID:
5877194
38.

[THE LAUGIER SIGN IN SEQUELAE OF COLLES FRACTURES].

ZERBI E, CIARAMELLA G.

Minerva Ortop. 1965 Mar;16:61-4. Italian. No abstract available.

PMID:
14331314
39.

[USE OF ANTIPERMEABILIZING AND CAPILLARY PROTECTOR DRUGS IN TRAUMATOLOGIC ORTHOPEDIC PRACTICE].

SIBILLA P, CIARAMELLA G.

Minerva Ortop. 1965 Mar;16:104-8. Italian. No abstract available.

PMID:
14331311
40.

[CLINICAL AND BIO-HUMORAL ASPECTS OF PATHOLOGIC FRACTURES DUE TO CARCINOMATOUS METASTASIS].

CIARAMELLA G, OTTAVIANI C.

Atti Accad Med Lomb. 1964 Aug-Dec;19:233-42. Italian. No abstract available.

PMID:
14301712
41.

[OBSERVATIONS ON SERUM LACTATE DEHYDROGENASE ACTIVITY IN OSTEOMYELITIS].

CIARAMELLA G, RIENZO C.

Atti Accad Med Lomb. 1964 Aug-Dec;19:288-9. Italian. No abstract available.

PMID:
14296707
42.

[CUTANEOUS TUBERCULINIC ALLERGOMETRY IN OSTEOARTICULAR TUBERCULOSIS].

BARBIERI E, CIARAMELLA G.

Atti Accad Med Lomb. 1964 Aug-Dec;19:271-3. Italian. No abstract available.

PMID:
14296703
43.

[OBSERVATIONS ON SYNOVIAL PERMEABILITY IN ARTICULAR PATHOLOGY].

RIENZO C, CIARAMELLA G.

Atti Accad Med Lomb. 1964 Aug-Dec;19:260-3. Italian. No abstract available.

PMID:
14296701
44.

[MALGAIGNE'S FRACTURE OF THE PELVIS].

CIARAMELLA G, DUSE G.

Atti Accad Med Lomb. 1964 Aug-Dec;19:225-32. Italian. No abstract available.

PMID:
14296697
45.

[ON FRACTURE OF THE STERNUM].

CIARAMELLA G, SIBILLA P.

Atti Accad Med Lomb. 1964 Aug-Dec;19:197-204. Italian. No abstract available.

PMID:
14296693
46.

[ON SOME CLINICAL AND METABOLIC ASPECTS OF HYPERPARATHYROIDISM. CONSIDERATIONS ON 5 CASES].

CIARAMELLA G, PARMEGGIANI A.

Arch Ortop. 1964;77:439-48. Italian. No abstract available.

PMID:
14316182
47.

[ON BENIGN OSTEOBLASTOMA (CASE REPORTS)].

CIARAMELLA G, GUALTIERI G.

Arch Ortop. 1964;77:217-23. Italian. No abstract available.

PMID:
14276598
48.

[ON SOME CLINICAL ASPECTS OF RECKLINGHAUSEN'S NEUROFIBROMATOSIS].

CIARAMELLA G.

Arch Ortop. 1964;77:211-6. Italian. No abstract available.

PMID:
14276597
49.

[TREATMENT OF HABITUAL PATELLA DISLOCATION].

CIARAMELLA G, ZERBI E.

Arch Ortop. 1964;77:207-10. Italian. No abstract available.

PMID:
14276596
50.

[FRACTURES OF THE VERTEBRAL ARCH].

CIARAMELLA G, CORRADI C.

Arch Ortop. 1964;77:135-45. Italian. No abstract available.

PMID:
14260505

Supplemental Content

Loading ...
Support Center